Proteomics of thyroid tumours provides new insights into their molecular composition and changes associated with malignancy

Juan Martínez-Aguilar1,2, Roderick Clifton-Bligh3 & Mark P. Molloy1,2

Around 5% of the general population have palpable thyroid nodules. Although most thyroid tumours are benign, thyroid cancer represents the most common malignancy of the endocrine system, comprising mainly follicular and papillary thyroid carcinomas. Previous studies have shed some light on the molecular pathogenesis of thyroid cancer but there have not been any comprehensive mass spectrometry-based proteomic studies of large scale to reveal protein expression differences between thyroid tumours and the molecular alterations associated with tumour malignancy. We applied data-independent acquisition mass spectrometry which enabled quantitative expression analysis of over 1,600 proteins from 32 specimens to compare normal thyroid tissue with the three most common tumours of the thyroid gland: follicular adenoma, follicular carcinoma and papillary carcinoma. In follicular tumours, we found marked reduction of the tumour suppressor and therapeutic target extracellular protein decorin. We made the novel observation that TGFβ3-induced protein ig-h3 (TGFBI) was found frequently overexpressed in follicular carcinoma compared with follicular adenoma. Proteomic pathway analysis showed changes in papillary carcinoma were associated with disruption of cell contacts (loss of E-cadherin), actin cytoskeleton dynamics and loss of differentiation markers, all hallmarks of an invasive phenotype.

Thyroid cancer is the most common endocrine malignancy. Around 5% of the general population have palpable thyroid nodules and this number increases to 50% with the use of ultrasonography1. Although most nodules are benign, there were estimated ~300,000 newly diagnosed thyroid cancer cases worldwide in 2012, 2.1% of all newly diagnosed cancers2. Most thyroid carcinomas arise from the thyroid follicular cells and the vast majority can be grouped into two histological types: follicular (10–15% of cases) and papillary (80–85% of cases) thyroid carcinoma or FTC and PTC, respectively, commonly referred to as differentiated thyroid carcinomas (DTC)3.

The World Health Organisation defines PTC as ‘a malignant epithelial tumour showing evidence of follicular cell differentiation and characterised by distinctive nuclear features’4. Accordingly, although the papillary architecture is a distinctive trait of classic PTC (two-thirds of cases), the formation of papillae is not a requirement for PTC diagnosis. On the other hand, the definition of FTC is based on malignancy and lack of the diagnostic nuclear features associated with PTC. About 50% of PTC cases present cervical lymph node metastasis (LNMI) and distant spread is present in up to 20% of FTC. Both histotypes present good overall prognosis but survival rates drop in older patients and in those with distant metastasis5,6. The mainstay of treatment for patients diagnosed with thyroid cancer is thyroidectomy, followed by ablation of remnant tissue with 131I and thereafter thyroid hormone replacement therapy.

From a clinical standpoint, an ancillary tool is needed to improve the cytological evaluation of ultrasound-guided fine needle aspiration (FNA) biopsy of patients with thyroid nodules. Given that the identification of FTC is based on the capsular or vascular invasion of neoplastic cells, it is apparent that follicular adenoma (FA) and FTC are indistinguishable by FNA cytology. In fact, the latter is able to discriminate between benign and malignant tumours only in 70–80% of cases. Moreover, only 20–30% of thyroid nodules diagnosed

1Department of Chemistry and Biomolecular Sciences, Macquarie University, NSW 2109, Australia. 2Australian Proteome Analysis Facility, Macquarie University, NSW 2109, Australia. 3Kolling Institute of Medical Research, Royal North Shore Hospital, St Leonards NSW 2065, Australia. Correspondence and requests for materials should be addressed to M.P.M. (email: mark.molloy@mq.edu.au)
Results

Proteomics profiles of follicular and papillary thyroid tumours show marked differences in protein expression. Figure 1 shows an overview of the sample preparation and mass spectrometry analysis carried out in this work. Using a subset of each thyroid tissue type we used mass spectrometry to establish a peptide spectral library of thyroid tissue that represented 2,682 proteins. Data-independent acquisition using SWATH mass spectrometry was then conducted for all 32 specimens (Supplementary Table S1). Quantitative values were able to be extracted for 1,629 proteins across all 32 samples, forming the basis for subsequent analyses. Hierarchical cluster analysis of protein expression based on ANOVA showed a clear separation of PTC tumours from all other sample groups and marked similarity between FA and FTC tumours (see Supplementary Fig. S1). Pairwise comparisons using histologically normal thyroid tissue as a reference group showed the number and pattern of molecular changes in FA and FTC to be clearly different from those in PTC tumours (see Fig. 2; original quantitative data can be found on the Supplementary dataset). Follicular tumours exhibited marked decreases in protein expression compared to normal thyroid tissue, whereas PTC samples showed decreased expression patterns of both over- and under-expression compared with normal tissue (Fig. 2). Out of a total of 86 and 71 differentially expressed proteins (fold-change \( \geq 2 \)) in FA and FTC, respectively, only 10 (FA) and 8 (FTC) genes were increased in these tumours (Supplementary Tables S2–S3). A rather different pattern was observed in PTC tumours which showed significant expression change of 184 proteins compared to normal thyroid tissue (91 up, 93 down) (Supplementary Table S4). Comparison of FA and FTC showed remarkable similarity of the respective proteomes, only TGF\( \beta \) proteomes, only TGF\( \beta \) was elevated in FTC (fold-change \( \geq 2 \)) (Supplementary Table S4). Newer proteomic approaches using advanced mass spectrometry enable deeper quantitative analyses revealing expression of thousands of proteins, sufficient to study biological pathways to improve our understanding in disease biology and propose new markers of diagnostic potential.

In this work, we used a data-independent acquisition mass spectrometry method known as SWATH17–19 to perform a global proteomic quantitative comparison of FA, FTC, PTC and normal (N) thyroid tissue. This led to the identification of over 2,600 proteins, providing the most comprehensive molecular proteome description of thyroid tumours to date. From this data we could glean new biological pathway insights on the distinctive molecular changes in these three common tumours of the thyroid gland.

Gene ontology and molecular pathway analyses. Gene Ontology enrichment analysis indicated over-representation, among others, of plasma membrane and extracellular proteins in the comparisons FTC/N and PTC/N (see Fig. 3). Additionally, the comparison PTC/N showed enrichment of cytoskeletal proteins and both PTC/N and FTC/FTC showed over-representation of the categories cell differentiation, cell motility and developmental process.

Canonical pathway analysis using the IPA software for the comparison FTC/N was led by the downregulation of acute phase and coagulation proteins including fibrinogen chains and alpha-2-macroglobulin (see Table 1). Although the expression of these proteins was also decreased in PTC with reference to normal samples, in the case of papillary tumours the top enriched pathways identified were ‘actin cytoskeleton signalling’ and ‘remodelling of epithelial adherens junctions’ (Table 1). Other enriched pathways were related to the activity of Rho family GTPases, which are known regulators of the actin cytoskeleton, cell-cell junctions and motility.

Protein expression changes in follicular-patterned tumours. Both follicular tumour types showed marked reduction (>10-fold) of the extracellular tumour suppressor proteoglycan decorin or PGS2 (see Figs 4 and 5), negative regulator of receptor tyrosine kinases and growth factor signalling. Additionally, FTC showed altered expression of other extracellular proteins that have been associated with tumourigenesis such as collagen alpha-1 (XV) chain, serpin H1 and tenascin20–22. The comparison of FA with FTC tumours revealed that the 72 kDa extracellular protein TGF\( \beta \) could correctly separate most FTC samples from the FA group with a relatively high fold change (see Fig. 6a). Subsequently, we used two alternative mass spectrometry approaches (isobaric stable-isotope labelling iTRAQ-MS, Fig. 6b) and high resolution multiple reaction monitoring (MRM-HR; Supplementary Fig. S2) to confirm the differential expression of TGF\( \beta \). The fact that the expression of most proteins remained unchanged between FA and FTC is
a clear demonstration of the high similarity of the molecular phenotype of these two histotypes and underscores why it has been difficult to obtain a molecular signature of malignancy among tumours with follicular histology.

**PTC tumours exhibit several distinctive proteomic changes.** The comparison of PTC tumours with normal samples readily identified many proteins commonly associated with the papillary histotype (e.g. annexin A1, thymosin β10, galectin-3, cytokeratin 19, ICAM-1, UDP-glucose 4-epimerase, cellular retinoic acid-binding protein 1, fibronectin, S100A6,9–12,15,23,24; see Supplementary Table S4), hence validating the analyses shown here. Also, thyroid-specific proteins, thyroid peroxidase (TPO) and iodotyrosine dehalogenase 1 (DEHAL1) were found at reduced levels in PTC, a feature also previously observed by transcriptomic studies9. The expression of these proteins was not changed in follicular tumours. Many of the proteins with altered expression between PTC and normal samples were also identified in the comparison PTC/FTC (Supplementary Table S5).

**Altered expression of a common subgroup of proteins is found in malignant FTC and PTC tumours.** FTC and PTC tumours shared dysregulation of 39 proteins with respect to normal thyroid tissue (Supplementary Table S6), including anterior gradient homolog 2 (AGR2), tenascin, extracellular superoxide dismutase (SOD3), 14-3-3 gamma, immunoglobulin superfamily containing leucine-rich repeat protein (ISLR), biotinidase and trefoil factor 3 (TFF3). Interestingly, the magnitude of expression of AGR2, tenascin, SOD3 and TFF3 was larger in PTC (see Fig. 7).
Validation of protein expression. iTRAQ-MS analysis of FA, FTC and PTC samples confirmed the differential expression of most proteins (see Fig. 6 and Supplementary Table S7) and was well correlated with SWATH-MS ($r^2 = 0.84$), serving as a general validation of the label-free quantitation approach. Additionally, the expression of several proteins (decorin, TGFBI, TPO, AGR2, SOD3, TFF3, tenascin, Arp2/3 proteins p41-ARC and p20-ARC, biotinidase, serpin H1 and E-cadherin) was further confirmed by targeted analysis using MRM-HR (see Supplementary Fig. S2).

Western blot of decorin proteoglycan in normal, PTC, FA and FTC samples also confirmed loss of expression in tumours with follicular growth pattern FA and FTC (Fig. 8). The broad molecular weight bands observed in some patient samples are consistent with heterogeneous glycosylation.

Discussion

The significantly different number of protein changes and patterns of protein over- and under-expression in follicular and papillary tumours determined by mass spectrometry closely reflect known histological and clinico-pathological features of thyroid tumours. Due to extensive quantitative comparison of over 1,600 proteins across 32 specimens our analysis provides the most comprehensive proteomic landscape analysis of thyroid tumours to date. Although FTC is more likely to metastasize to distant organs than PTC, this occurs with much less frequency than lymphatic metastasis in PTC. Since we studied only LNM-positive PTC cases, our results may help to explain the common metastatic phenotype of PTC as compared with the benign (FA) and minimally invasive follicular tumours (FTC).

A striking observation was the loss of the proteoglycan decorin in follicular tumours FA and FTC compared to non-neoplastic thyroid tissue. No significant change was seen in PTC, suggesting an important role of decorin in follicular thyroid neoplasia. Importantly, our novel protein expression data discovered by mass spectrometry and supported by immunoblot are consistent with a study that measured decorin mRNA abundance in thyroid tumours by quantitative polymerase chain reaction (qPCR). Arnaldi et al. found significant decrease of decorin mRNA in FA and FTC with respect to normal tissues but not in PTC. Moreover, lower decorin mRNA levels were also found in the follicular variant of PTC, therefore associating decorin loss with follicular-patterned thyroid tumours. Decorin is the prototypic member of the small leucine-rich proteoglycans (SLRP) family and has been recognised as a multifaceted anti-oncogenic protein of the tumour microenvironment, regulating key cellular functions including proliferation, survival and migration. It also negatively regulates TGFβ signalling and has been found to induce paternally expressed gene 3 (Peg3), a master regulator of endothelial cell autophagy, thereby supporting decorin's angiogenic suppressive activity. Taken together, decorin loss facilitates
tumour growth and progression and its markedly reduced expression in follicular thyroid tumours warrants further investigations. Several studies have shown that decorin reduces tumour growth and metastasis and is therefore currently considered an attractive therapeutic target that could also be useful in thyroid tumours of follicular histology.

Several molecular markers and mutational status have been proposed to aid in the diagnosis of thyroid tumour malignancy including a recent expression classifier employing 167 genes to distinguish benign thyroid nodules among those with indeterminate FNA cytology. This suggests that several markers would be needed in order to detect follicular thyroid cancer. Indeed, we have found that the proteomic profiles of FA and FTC from our cohort are highly similar; however, we also found that the elevated expression of the extracellular protein TGFBI was able to differentiate 6 out of 8 FTC from FA specimens (Fig. 6), which comprise the two main types of thyroid tumours in the indeterminate category of FNA biopsies. Notably, increased TGFBI expression has also been shown in a mouse model of FTC progression. Kim et al. studied the changes in the gene expression profile of *ThrbPV/PV* mice, which spontaneously develop metastatic FTC as they age. The TGFBI gene expression was dramatically upregulated during the course of the disease and up-regulation was confirmed at the protein level.

Altogether, the consistent lower expression of TGFBI in all FA samples as compared to FTC cases, supported with previously observed in vivo upregulation, suggest that TGFBI is a protein that could be involved in the progression from thyroid adenoma to carcinoma and is therefore a novel candidate marker of malignancy in follicular thyroid tumours. Future investigations with larger sample cohorts will help to evaluate its diagnostic utility. It is interesting that TGFBI is known to participate in the dynamics of the extracellular space, building upon the idea of a significant role of the tumour microenvironment in FTC, including loss of decorin.

As indicated by the pathway analysis, the comparison of follicular tumours with normal samples showed decreased expression of some acute phase proteins including members of the coagulation system. It is known that thyroid dysfunction influences the haemostatic balance and benign thyroid disorders such as hyperthyroidism and subclinical hypothyroidism have been linked to enhanced coagulation states, which may explain the decreased expression of these proteins in this tumour samples. On the other hand, the comparison of PTC tumours with normal samples confirmed differential expression of several proteins commonly associated to this histotype. PTC tumours showed underexpression of thyroid function-related proteins TPO, DEHAL1 and
thyroglobulin (TG), consistent with the de-differentiation of cellular function. Pathway analysis revealed differential expression of key proteins involved in cell migration and mapped to molecular pathways such as actin cytoskeleton signalling and remodelling of epithelial adherens junctions. Not unexpectedly, these changes were similarly observed in the comparison PTC/FTC, again highlighting the unique and divergent proteomic profile of papillary tumours.

Disruption of adherens junctions destabilises the cell-cell contacts and provides the cells with migratory potential, which in the case of tumour cells can lead to the onset of metastasis. Consistent with their LNM-positive status, we have found that PTC tumours exhibit lower levels of E-cadherin, the core protein in adherens junctions. Our results and previous studies support the concept of E-cadherin as a tumour suppressor in PTC. Using immunofluorescence, Brabant et al. found frequent, albeit heterogeneous, reduction of E-cadherin in PTC and almost total loss in anaplastic thyroid carcinoma. LNM-positive samples showed undetectable immunoreactivity. A separate study by Naito et al. employing immunohistochemistry (IHC) found decreased expression of E-cadherin in PTC compared with normal and FA tissues, an event more markedly seen in samples from patients with LNM.

In PTC tumours, we also found overexpression of key proteins associated with remodelling of the actin cytoskeleton and cell locomotion. For example, several members of the Arp2/3 complex, actin, profilin-1, thymosin β4 and β10. The Arp2/3 complex is a master regulator of actin polymerisation at the leading edge of membrane protrusions of motile cells called lamellipodia. Upregulated expression of Arp2/3 subunits has been found...
in both neoplastic and different stromal cells of invasive colorectal cancer and likewise the possible contribution of the stromal component in PTC should be acknowledged. Thymosin \( \beta_4 \) and \( \beta_{10} \) are two polypeptides that act as actin sequesters that prevent polymerisation and form a reservoir of G-actin that can be released when needed to supply actin to filament ends. Thymosin \( \beta_{10} \) expression has been correlated with tumour malignancy in thyroid cancer. Other overexpressed proteins associated with the actin cytoskeleton and cell motility that we detected include coronin proteins and zyxin.

PTC and FTC tumours presented a group of common dysregulated proteins including SOD3, ISLR, biotinidase, polymerase I and transcript release factor (cavin-1), TFF3, alpha(B)-crystallin (CryAB), AGR2, tenascin and 14-3-3 gamma. Several of them showed larger expression change in PTC and it is tempting to speculate that it is related to the more aggressive LNM-positive PTC phenotype. Our results are in line with previous reports regarding the expression of several of these proteins in thyroid cancer. For example, an earlier study found decreased biotinidase expression in PTC tumours compared with benign tissues including follicular adenomas. Nevertheless, we show here that biotinidase downregulation is common to both follicular and papillary

Figure 5. Extracted ion chromatograms (XIC) of example peptides (sequence shown) corresponding to different proteins in the sample groups. Arrow indicates peptide retention time (min) for ion extraction and intensity is ion counts per second. Coloured traces refer to XIC for various product ions for each peptide.

Figure 6. Relative expression of TGFBI in FA and FTC tumours as determined by (a) SWATH and (b) iTRAQ analysis; **p < 0.01, ***p < 0.001.
tumours and is a potential general marker of thyroid neoplasia. Decreased expression of cavin-1 in FTC and PTC is in agreement with its downregulation in other tumours including prostate cancer where its expression has been shown to reduce cell migration, tumour growth, angiogenesis and lymphangiogenesis, therefore acting as a potential tumour suppressor. Downregulation of carbonic anhydrases (CA) CA1, CA2 and CA4 was a common feature of thyroid tumours, which may be related to lower erythrocyte abundance since we found other erythrocyte proteins to be downregulated, including bisphosphoglycerate mutase; spectrin beta chain and haemoglobin subunits HBA, HBB and HBD.

Both thyroid carcinomas showed increased levels of other key proteins with known carcinogenic roles such as tenascin and AGR2. Tenascin elevation is in keeping with its high expression in most solid tumours and several reports suggesting involvement in tumour cell proliferation, angiogenesis and metastasis. Other reports have documented the pro-oncogenic activity of AGR2 in various types of cancer, supported by in vivo experiments showing increased tumour growth and metastasis derived from AGR2-expressing cells. Recent studies show that AGR2 acts as a thioredoxin in the endoplasmic reticulum (ER), interacting directly with EGFR for disulfide bond formation and protein folding and determining its presentation to the cell surface. Functional EGFR overexpression has been found in thyroid cancer cells and AGR2 upregulation in PTC has also been demonstrated.

In summary, we performed an extensive global proteomic comparison of the three most common thyroid tumours, PTC, FTC and FA. Importantly, besides our own confirmation of results by two mass spectrometry
methods, several of our results are consistent with previous reports utilising immunohistochemical or mRNA expression analyses or in vivo functional studies. Extracellular matrix proteins were found to play a predominant role in the differential protein expression profiles of follicular thyroid tumours, particularly the loss of the anti-oncogenic protein and therapeutic target decorin. Moreover, we found that minimally invasive FTC tumours have frequent overexpression of TGFBI with respect to follicular adenomas, consistent with the results in a mouse model of FTC. PTC was characterised by destabilisation of cell-cell contacts, increased expression of key regulators of the actin cytoskeleton and under-expression of thyroid differentiation markers. Finally, through the use of comprehensive mass spectrometry-driven characterisation our study has provided a wealth of new information to further understand the molecular pathological basis of thyroid tumours.

Methods

**Samples.** Eight fresh frozen thyroid tissues from each sample group (normal histology, FA, minimally invasive FTC and classic PTC) were analysed by SWATH mass spectrometry. Two additional PTC samples and one additional FA sample were included for iTRAQ-MS analysis (Supplementary Table S1). All samples were obtained from the Kolling Institute of Medical Research, Sydney. Histologically normal samples were obtained from dissection of non-neoplastic tissue from the contralateral lobe of patients who had undergone thyroidectomy or from patients with benign disease where thyroidectomy was indicated. All PTC cases showed lymph node metastasis. The experimental protocols were approved by the human research ethics committees of the Northern Sydney Local Health District (1303–091M) and Macquarie University (5201300037). Informed consent was obtained from all subjects. All experiments were carried out in accordance with these approvals. Figure 1 shows an overview of the methods employed in this work.

**Sample preparation.** All samples were lysed on ice with sonication in 20 mM HEPES, 1% sodium deoxycholate (SDOC), 0.1% SDS, 150 mM NaCl, and 1 mM EDTA, pH 8, with complete, EDTA-free protease inhibitor cocktail (Roche) and phosphatase inhibitor tablet (Thermo Scientific Pierce). Lysates were centrifuged (12,000 g, 10 min, 4°C) and the supernatants retained. After protein quantitation (BCA method), 10 μg of protein were reduced in 10 mM dithiothreitol (DTT; 30 min, 60°C), alkylated with 50 mM iodoacetamide (IAA; 30 min in the dark), diluted to 50 μL with 1% SDOC and incubated at 37°C overnight with 0.2 μg of sequencing grade modified trypsin. After protein digestion, samples were acidified with 1 μL of formic acid and the precipitate was removed by centrifugation (14000 g, 10 min).

The spectral library for SWATH analysis was generated by combination of MS/MS spectra from six unfraccionated (two normal, two PTC, one FA and one FTC) and eight strong anion-exchange (SAX) fractionated peptide samples (two from each thyroid tissue type). SAX fractionation was performed following the method described by Wiśniewski et al.90 at pH 11, 8, 5 and 3.

iTRAQ labelling was carried out using iTRAQ reagent 4-plex kit (AB Sciex). 100 μg of protein from all FA, FTC and PTC samples (including a masterpool of equal amounts of each sample) were treated with 5 mM tris-(2-carboxyethyl) phosphine (TCEP) for 1h at 60°C and then with 10 mM cysteine blocking reagent, methyl methanethiosulfonate (MMTS) for 10 min at RT. Samples were diluted with 1% SDOC in 500 mM triethylammonium bicarbonate (TEAB) before trypsin digestion at 37°C for 16h. SDOC was removed by precipitation with formic acid and centrifugation (14000 g, 10 min) and the supernatants were dried in speed-vac and kept at –80°C until use. Samples were analysed in groups consisting of a masterpool aliquet, a FA, a PTC and a FTC specimen. Peptide samples were reconstituted with 1M TEAB and labelled with iTRAQ isobaric tags in 100% ethanol for 1 h at RT. The reaction was quenched with Milli-Q water and labelled digests were combined in equal ratios. Before LC-MS analysis, desalted samples were fractionated by strong cation exchange with an Agilent 1260 LC, PolySULFOETHYL A column (200 μm i.d. × 15 cm, 3 μm particle size) with a 120 min gradient using 0.1% FA/90% ACN (v/v) as weak and 0.1% FA (v/v) in ACN as weak and strong elution solvents, respectively. The LC system was coupled to a TripleTOF 6600 mass spectrometer (AB Sciex), where we employed SWATH-MS. To this end, we first built a reference spectral library by information-dependent analysis (IDA) of six different samples (two normal, two PTC, one FA and one FTC) and the eight samples prepared by SAX fractionation (two from each thyroid tissue type). Mass spectrometry conditions during IDA analysis were as follows: spray voltage-2.5 kV, interface heater temperature-150°C, survey scan time-250 ms over the m/z range 350–1500, MS/MS with rolling collision energy of the 20 most intense precursor ions with charge states 2+ to 4+ and above 200 c.p.s., MS/MS accumulation time-100 ms in high sensitivity mode and dynamic exclusion of 30 s within 50 ppm. For SWATH-MS, 100 windows of variable m/z range and 50 ms accumulation time were employed, covering the precursor mass range of 350–1500 m/z. MS/MS scans with accumulation time of 30 ms were acquired in high sensitivity mode, resulting in a total cycle time of ~3.1 s and 8–10 points on average across peaks.

For the iTRAQ-labelled samples, 18 SCX fractions from each sample were selected based on the UV responses and preliminary tests on the number of non-redundant proteins identified in each SCX fraction. The latter were resuspended in 40 μL of 0.1% TFA, 2% ACN (v/v) in water, loaded sequentially onto a peptide trap and separated on an C18 Protocel column (100 mm × 150 μm, 3 μm) with a 2-hour gradient using 0.1% FA/90% ACN (v/v) as...
strong solvent and an Eksigent LC system at a flow rate of 600 nL/min. The LC system was coupled to a TripleTOF 5600 mass spectrometer (AB Sciex). The spray voltage was set at 2.5 kV, with interface heater temperature of 150 °C. Mass spectrometry analysis was performed in IDA mode selecting the 10 most intense precursor ions over the m/z range 400–1500 with survey scan time of 250 ms at high resolution mode. MS/MS accumulation time was 200 ms, recorded in high sensitivity mode. Ions with 2+ to 5+ charge states were selected for MS/MS with dynamic exclusion of 20 s within 50 ppm, rolling collision energy and iTRAQ collision energy adjustment selected.

For the MRM-HR analyses, LC conditions were the same as in SWATH-MS. Peptide sequences and MS conditions can be found on Supplementary Table S8.

**Protein identification and quantitative analysis.** IDA MS files from the groups of SAX-fractionated and unfractionated samples were processed using ProteinPilot 5.0 software with the Paragon database search algorithm. MS/MS spectra were searched against the UniProtKB/Swiss-Prot human protein database 2014_04 with 20,265 entries. Up to two missed cleavages were allowed and identification was performed considering cysteine alkylation by iodoacetamide, biological modifications and protein minimum confidence score of 95% (detected protein threshold >1.3) with FDR analysis enabled. The Paragon group files were imported into PeakView 2.1 software with SWATH acquisition MicroApp 2.0, shared peptides were excluded and the ion libraries from unfractionated and fractionated samples were exported to create an extended ion library using the list of ions from unfractionated samples as a seed spectral library. Only the following peptide modifications were kept: cysteine alkylation and protein N-terminal acetylation. A quality check was carried out to ensure that the relative intensities of fragment ions matched between the seed and add-on libraries. The precursor retention time of peptides passing these criteria was aligned to the seed library by supervised learning-based linear regression modelling on common peptides. For peptides with conflicting or overlapping spectra between seed and add-on libraries, only seed library peptides were kept and protein accessions were consolidated in an extended spectral library. The latter was then used for peptide identification in the SWATH files considering up to 100 peptides per protein, 6 transitions per peptide, 99% peptide confidence, 1% FDR, fragment ion extraction window of 10 min and mass tolerance of 75 ppm. In the SWATH acquisition MicroApp, selection of fragment ions depends on m/z and intensity, giving priority to ions of the greatest intensity above the precursor mass window and ions above y3 and b3 ions. The lists of identified proteins, peptides and their corresponding peak area and FDR were exported and the data were further filtered to keep only peptides with FDR ≤ 1% in at least five out of eight samples in each group (normal, FA, FTC, PTC) and remove reverse protein hits.

Data from the iTRAQ analysis were processed using the ProteinPilot 4.2 software using the following parameters: sample type - iTRAQ 4-plex; cysteine alkylation - TMTS; digestion – trypsin; ID focus - biological modifications and amino acid substitutions; search effort – thorough ID. FDR analysis was carried out with detected protein threshold (Unused ProtScore) set at 0.05. Automatic bias correction was selected for calculation of protein ratios. Proteins corresponding to local FDR <5% and global FDR <1% were selected for further analyses.

**Statistical analysis.** The statistical analysis of SWATH data was performed on Perseus 1.5. Peak areas were log-transformed and normalised based on the median value in each of the thirty-two samples. Differentially expressed proteins in pairwise comparisons were identified by two-sided t-test (p < 0.05) and fold change fc ≥ 2. To account for multiple testing, we applied a permutation-based FDR analysis and report the corresponding q values. Spectral data of proteins with only one peptide were inspected manually and kept only the ones with clear peak co-elution, peak shape similarity and distinction from the noise level (see Supplementary Fig. S3 for some examples). To compare all four sample groups we applied one-way ANOVA p < 0.05. Heat maps were generated by hierarchical clustering with Euclidean distance and average linkage. For the iTRAQ validation data, protein abundances in each tumour type were first compared against those in the masterpool for each iTRAQ run and change of protein expression was identified based on a two-sided t-test p-value < 0.05 carried out on log-transformed iTRAQ ratios, considering only proteins detected in more than half of the cases and iTRAQ ratio > 1.2.

**Gene ontology and pathway analysis.** The list of proteins across all four sample groups and the differentially expressed sets of proteins from all comparisons were annotated and summarized at various gene ontology categories using the PloGO R package21. Each set of differentially expressed proteins was compared to the global set of identified proteins using the same software and enriched categories were identified based on a Fisher exact test p-value < 0.01. Protein placement in canonical pathways was undertaken using QIAGEN’s Ingenuity® Pathway Analysis (IPA®, QIAGEN Redwood City, www.qiagen.com/ingenuity).

**Western blot.** Immunoblotting was performed as previously described23. Briefly, 15 μg of protein were separated on 4–12% Bis-Tris NuPAGE gel and electrophorized onto nitrocellulose. The membrane was blocked with 5% skim milk, cut in two sections around 30 kDa and incubated overnight at 4 °C with either mouse monoclonal anti-decorin (1 μg/mL, clone 115402 R&D Systems) or rabbit monoclonal anti-Rab7a (1:500, Cell signalling). The secondary antibodies were fluorescence-labelled IRDye 800CW donkey anti-mouse and goat anti-rabbit IgG (LI-COR), incubated at RT for 1 h, visualised and quantitated using an Odyssey infrared imaging system and software (LI-COR, Lincoln, NE). Densitometry values were obtained using a fixed size rectangle feature enclosing the band of interest to obtain the intensity output after background subtraction (median intensity of pixels around the rectangle area). Measured values for decorin were divided by Rab7a values (reference control23) to compare decorin expression across samples.
References

1. Gharib, H. & Papini, E. Thyroid nodules: clinical importance, assessment, and treatment. Endocrinol Metab Clin North Am 36, 707–35, vi (2007).
2. Ferlay, J. et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr, accessed on 04/08/2015.
3. Nikiforov, V. E. & Nikiforova, M. N. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol 7, 569–80 (2011).
4. DeLellis, R., Lloyd, R., Heitz, P. & Eng, C. (eds.) WHO classification of tumours. Pathology and genetics of tumours of the endocrine organs (IARC press, Lyon, France, 2004).
5. Kondo, T., Ezzat, S. & Asa, S. L. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 6, 292–306 (2006).
6. Cibas, E. S. & Ali, S. Z. The Bethesda System For Reporting Thyroid Cytopathology. Am J Clin Pathol 132, 658–65 (2009).
7. Haugen, B. R., Woodmansee, M. W. & McDermott, M. T. Towards improving the utility of fine-needle aspiration biopsy for the diagnosis of thyroid tumours. Clin Endocrinol (Oxf) 56, 281–90 (2002).
8. Cooper, D. S. et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19, 1167–214 (2009).
9. Fugarewicz, K. et al. A multi-gene approach to differentiate papillary thyroid carcinoma from benign lesions: gene selection using support vector machines with bootstrapping. Endocr Relat Cancer 14, 809–26 (2007).
10. Fischer, S. & Asa, S. L. Application of immunohistochemistry to thyroid neoplasms. Arch Pathol Lab Med 132, 359–72 (2008).
11. Cassol, C. A. & Asa, S. L. Molecular pathology of thyroid cancer. Diag Histopathol 17, 124–139 (2011).
12. Brown, L. M. et al. Quantitative and qualitative differences in protein expression between papillary thyroid carcinoma and normal thyroid tissue. Mol Carcinog 45, 613–26 (2006).
13. Neta-Maier, R. T. et al. Discovery and Validation of Protein Abundance Differences between Follicular Thyroid Neoplasms. Cancer Res 68, 1572–1580 (2008).
14. Sofiadis, A. et al. Proteomic profiling of follicular and papillary thyroid tumors. Eur J Endocrinol 166, 657–67 (2012).
15. Sofiadis, A. et al. Proteomic study of thyroid tumors reveals frequent up-regulation of the Ca2+-binding protein S100A6 in papillary thyroid carcinoma. Thyroid 20, 1067–76 (2010).
16. Walther, T. C. & Mann, M. Mass spectrometry-based proteomics in cell biology, J Cell Biol 190, 491–500 (2010).
17. Sajic, T., Liu, Y. & Aebersold, R. Using data-independent, high-resolution mass spectrometry in protein biomarker research: perspectives and clinical applications. Proteomics Clin Appl 9, 307–21 (2015).
18. Guo, T. et al. Rapid mass spectrometric conversion of tissue biopsy samples into permanent quantitative digital proteome maps. Nat Med 21, 407–413 (2015).
19. Gillet, L. C. et al. Targeted Data Extraction of the MS/MS Spectra Generated by Data-independent Acquisition: A New Concept for Mass Spectrometry and Accurate Proteome Analysis. Mol Cell Proteomics 11 (2012).
20. Clementa, A. G. & Harris, A. Collagen XV: exploring its structure and role within the tumor microenvironment. Mol Cancer Res 11, 1481–6 (2013).
21. Zhu, J. et al. Chaperone Hsp47 Drives Malignant Growth and Invasion by Modulating an ECM Gene Network. Cancer Res 75, 1580–91 (2015).
22. Orend, G. & Chiquet-Ehrismann, R. Tenascin-C induced signaling in cancer. Cancer Lett 244, 143–63 (2006).
23. Martinez-Aguilar, J., Clifton-Bligh, R., & Molloy, M. P. A multiplexed, targeted mass spectrometry assay of the S100 protein family uncovers the isoform-specific expression in thyroid tumours. BMC Cancer 15, 199 (2015).
24. Zhang, X. J. et al. Thyminosin beta 10 correlates with lymph node metastases of papillary thyroid carcinoma. J Surg Res 192, 487–93 (2014).
25. Weber, I. T., Harrison, R. W. & Iozzo, R. V. Model structure of decorin and implications for collagen fibrillogenesis. J Biol Chem 271, 31767–70 (1996).
26. Arnaldi, L. A., Borra, R. C., Maciel, R. M. & Cerutti, J. M. Gene expression profiles reveal that DCN, DIO1, and DIO2 are underexpressed in benign and malignant thyroid tumors. Thyroid 15, 210–21 (2005).
27. Soleu Feugain, D. D., Gotte, M. & Viola, M. More than matrix: the multifaceted role of decorin in cancer. Eur J Cancer 42, 11–1 (2006).
28. Neill, T., Schaefer, L. & Iozzo, R. V. Decorin: a guardian from the matrix. Am J Pathol 181, 380–7 (2012).
29. Buraschi, S. et al. Decorin causes autophagy in endothelial cells via Peg3. Proc Natl Acad Sci USA 110, E2582–91 (2013).
30. Reed, C. C., Gauldie, J. & Iozzo, R. V. Suppression of tumorigenicity by adenovirus-mediated gene transfer of decorin. Oncogene 21, 3688–95 (2002).
31. Tralhao, J. G. et al. In vivo selective and distant killing of cancer cells using adenosinomediated decorin gene transfer. FASEB J 17, 464–6 (2003).
32. Hu, Y. et al. Decorin suppresses prostate tumor growth through inhibition of epidermal growth factor and androgen receptor pathways. Neoplasia 11, 1042–53 (2009).
33. Goldberg, N. et al. An antimitastic role for decorin in breast cancer. Am J Pathol 173, 844–55 (2008).
34. Alexander, E. K. et al. Preoperative Diagnosis of Benign Thyroid Nodules with Indeterminate Cytology. N Engl J Med 367, 705–715 (2012).
35. Kim, D. W. et al. Preoperative Diagnosis of Benign Thyroid Nodules with Indeterminate Cytology. N Engl J Med 367, 705–715 (2012).
36. Kim, D. W. Walker, R. L., Meltzer, P. S. & Cheng, S. Y. Complex temporal changes in TGFbeta oncogenic signaling drive thyroid carcinogenesis in a mouse model. Carcinogenesis 34, 2389–400 (2013).
37. Vescovi, P. P. et al. The spectrum of coagulation abnormalities in thyroid disorders. Semin Thromb Hemost 37, 7–10 (2011).
38. Birchmeier, W. & Behrens, J. Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness, Biochim Biophys Acta 1199, 11–26 (1994).
39. Brabant, G. et al. E-cadherin: a differentiation marker in thyroid malignancies. Cancer Res 53, 4987–93 (1993).
40. Naito, A., Inase, H., Kuzushima, T., Nakamura, T. & Kobayashi, S. Clinical significance of E-cadherin expression in thyroid neoplasms. J Surg Oncol 76, 176–80 (2001).
41. Goley, E. D. & Welch, M. D. The ARP2/3 complex: an actin nucleator comes of age. Nat Rev Mol Cell Biol 7, 713–26 (2006).
42. DeLellis, R., Lloyd, R., Heitz, P. A., & Jessurun, J. Application of Arp2/3 complex in the process of colorectal carcinogenesis. Mod Pathol 17, 461–7 (2004).
43. Huff, T. Muller, C. S., Otto, A. M., Netzker, R. & Hannappel, E. Beta-Thymosins, small acidic peptides with multiple functions. Int J Biochem Cell Biol 33, 205–20 (2001).
44. Califano, D. et al. Thyminosin beta10 gene overexpression correlated with the highly malignant neoplastic phenotype of transformed thyroid cells in vivo and in vitro. Cancer Res 58, 823–8 (1998).
45. So, A. K. et al. Biotinidase is a novel marker for papillary thyroid cancer aggressiveness. PLoS One 7, e40956 (2012).
46. Nazzar, Z. D. et al. PVR/Carfin-1 decreases prostate cancer angiogenesis and lymphangiogenesis. Oncotarget 4, 1844–55 (2013).
47. Wang, Z., Hao, Y. & Lowe, A. W. The adenocarcinoma-associated antigen, AGR2, promotes tumor growth, cell migration, and cellular transformation. Cancer Res 68, 492–7 (2008).
48. Dong, A., Wodziak, D. & Lowe, A. W. Epidermal growth factor receptor (EGFR) signaling requires a specific endoplasmic reticulum thioredoxin for the post-translational control of receptor presentation to the cell surface. J Biol Chem 290, 8016–27 (2015).
49. Yeh, M. W. et al. Differentiated thyroid cancer cell invasion is regulated through epidermal growth factor receptor-dependent activation of matrix metalloproteinase (MMP)-2/gelatinase A. Endocr Relat Cancer 13, 1173–83 (2006).
49. Di Maro, G. et al. Anterior gradient protein 2 promotes survival, migration and invasion of papillary thyroid carcinoma cells. *Mol Cancer* **13**, 160 (2014).

50. Wisniewski, J. R., Zougman, A. & Mann, M. Combination of FASP and StageTip-based fractionation allows in-depth analysis of the hippocampal membrane proteome. *J Proteome Res* **8**, 5674–8 (2009).

51. Pascovici, D., Keighley, T., Mirzaei, M., Haynes, P. A. & Cooke, B. PloGO: plotting gene ontology annotation and abundance in multi-condition proteomics experiments. *Proteomics* **12**, 406–10 (2012).

**Acknowledgements**

Aspects of this research were conducted at the Australian Proteome Analysis Facility, facilitated by the Australian Government’s National Collaborative Research Infrastructure Scheme. MPM acknowledges support of Cancer Institute NSW through funding of Sydney Vital Translational Cancer Research Centre. We thank Dr. Dana Pascovici and Dr. Jemma Wu for assistance with bioinformatics analysis.

**Author Contributions**

J.M.-A. designed, performed experiments, analysed data and wrote the manuscript. R.C.-B. designed experiments, interpreted data. M.P.M. designed and supervised experiments, interpreted data and wrote the manuscript. All authors reviewed the manuscript.

**Additional Information**

**Accession code:** The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD002732.

**Supplementary information** accompanies this paper at http://www.nature.com/srep

**Competing financial interests:** The authors declare no competing financial interests.

**How to cite this article:** Martínez-Aguilar, J. et al. Proteomics of thyroid tumours provides new insights into their molecular composition and changes associated with malignancy. *Sci. Rep.* **6**, 23660; doi: 10.1038/srep23660 (2016).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/